AXL Mediates Resistance to PI3Kα Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas-Reference-Cited by-同舟云学术

AXL Mediates Resistance to PI3Kα Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas

Published:2015-04 Issue:4 Volume:27 Page:533-546
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

Elkabets Moshe,Pazarentzos Evangelos,Juric Dejan,Sheng Qing,Pelossof Raphael A.,Brook Samuel,Benzaken Ana Oaknin,Rodon Jordi,Morse Natasha,Yan Jenny Jiacheng,Liu Manway,Das Rita,Chen Yan,Tam Angela,Wang Huiqin,Liang Jinsheng,Gurski Joseph M.,Kerr Darcy A.,Rosell Rafael,Teixidó Cristina,Huang Alan,Ghossein Ronald A.,Rosen Neal,Bivona Trever G.,Scaltriti Maurizio,Baselga José

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Oncology

Reference41 articles.

1. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1;Agrawal;Science,2011

2. Overexpression of PIK3CA is associated with lymph node metastasis in esophageal squamous cell carcinoma;Akagi;Int. J. Oncol.,2009

3. Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck

4. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck;Bonner;N. Engl. J. Med.,2006

5. AXL mediates resistance to cetuximab therapy;Brand;Cancer Res.,2014

Cited by 264 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dual inhibition of EGFR and PI3K with a single drug;Nature Cancer;2024-08-16

2. Coordinated Targeting of S6K1/2 and AXL Disrupts Pyrimidine Biosynthesis in PTEN-Deficient Glioblastoma;Cancer Research Communications;2024-08-01

3. A bispecific antibody targeting EGFR and AXL delays resistance to osimertinib;Cell Reports Medicine;2024-08

4. A first-in-class selective inhibitor of EGFR and PI3K offers a single-molecule approach to targeting adaptive resistance;Nature Cancer;2024-07-11

5. Elucidating the phosphoregulatory network of predominant phosphosite in AXL kinase: an integrative bioinformatic approach;Journal of Proteins and Proteomics;2024-06-19